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Abstract 
Preimplantation Genetic Diagnosis (PGD) testing is the practice of obtaining a cellular biopsy sample 
from a developing human oocyte or embryo, acquired via a cycle of In Vitro Fertilization (IVF); 
evaluating the genetic composition of this sample; and using this information to determine which 
embryos will be optimal for subsequent uterine transfer. PGD has become an increasingly useful adjunct 
to IVF procedures. The ability to provide couples who are known carriers of genetic abnormalities the 
opportunity to deliver healthy babies has opened a new frontier in reproductive medicine. The purpose of 
the PGD is enables us to choose which embryos will be implanted into the mother. In the present study we 
investigate the frequency of application of this technique in the kingdom and GCC to find out, the 
population awareness of these technique and the advantages which could apply to the community. We 
also interested to know frequencies of centers and studies in this field. This epidemiological study helps 
to improve social awareness and community services toward reducing frequencies of genetic disorders.  
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1. Introduction 
Preimplantation Genetic Diagnosis (PGD) is a new method used mainly for those who have high risk 
for transmitted genetic diseases to their children (Asscher & Koops, 2010) whatever they diagnosed 
with certain transmitted disease as adults or have a family history for transmitted disease. Also it can 
used for patients who have suffer of recurrent miscarriages (Asscher & Koops, 2010), unsuccessful IVF 
cycles (Asscher & Koops, 2010) and sever male factor infertility (Asscher & Koops, 2010). It is 
available for a large number of monogenic disorders due to a single gene only (autosomal recessive, 
autosomal dominant or X-linked) or of chromosomal structural aberrations. This helps these couples to 
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identify embryos carrying a genetic disease or a chromosome abnormality, thus avoiding diseased 
offspring (Asscher & Koops, 2010). The most frequently diagnosed autosomal recessive disorders are 
cystic fibrosis, Beta-thalassemia, sickle cell disease and spinal muscular atrophy type 1. The most 
common dominant diseases are myotonic dystrophy, Huntington’s disease and Charcot-Marie-Tooth 
disease; and in the case of the X-linked diseases, most of the cycles are performed for fragile X 
syndrome, haemophilia A and Duchenne muscular dystrophy (Basille, 2009). 
Edwards and Gardner preformed first known embryo biopsy in 1968 on rabbits (Bellavia, 2010). Then 
used in human first in United Kingdom along with PGD in the mid-1980s as alternative to prenatal 
diagnoses. In the beginning, PGD revolved to a new level where it can indirectly determine the gender 
of embryo and then they used it for avoiding X-linked diseases (Asscher & Koops, 2010). The first 
unaffected child born by using PGD were in 1989 in London and reported by Handyside and his groups, 
and they obtained the genetic sample from the cleavage stage and they also used PGD to an X-linked 
disease (Handyside, 1990). In addition, they used Polymerase Chain Reaction (PCR) method to detect 
segment of Y-chromosome. Nowadays, there is many hospitals doing PGD and in Saudi Arabia, there is 
more than 1600 cases done with PGD in King Faisal Specialist Hospital and Research Centre (Debrock, 
2010).  
PGD also can be used to select embryos to be without a genetic disorder, to have increased chances of 
successful pregnancy, to match a sibling in HLA type in order to be a donor, to have less cancer 
predisposition, and for sex selection (Dumoulin, 1998). 
Preimplantation Genetic Profiling (PGP) has been suggested as a method to determine embryo quality 
in in vitro fertilization, in order to select an embryo that appears to have the greatest chances for 
successful pregnancy (Figure 1) (Hardarson, 2008). However, as the results of PGP rely on the 
assessment of a single cell, PGP has inherent limitations as the tested cell may not be representative of 
the embryo because of mosaicism (Hardarson, 2008). 
Human Leukocyte Antigen (HLA) typing of embryos, so that the child’s HLA matches a sick sibling, 
availing for cord-blood stem cell donation (Hardarson, 2008). The child is in this sense a “savior 
sibling” for the recipient child (Hardarson, 2008).  
A more recent application of PGD is to diagnose late-onset diseases and cancer, such as Huntington 
disease (Asscher & Koops, 2010). Since affected individuals remain healthy until the onset of the 
disease, frequently in the fourth decade of life (Asscher & Koops, 2010).  
Preimplantation Genetic Diagnosis provides a method of prenatal sex discernment even before 
implantation, and may therefore be termed preimplantation sex discernment. Potential applications of 
preimplantation is sex discernment in gene testing for monogenic disorders whose presentation is 
linked to the sex, such as X-linked diseases. 
The idea of PGD is to do test before pregnancy occur, these to avoid any chance of have baby with an 
affected genetic disorders. This procedure can be done in in three main stages: the oocyte and zygote 
stage (occur in day 0 and day 1) via polar body biopsy; the cleavage stage (day 3) employing 
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blastomere biopsy; the blastocyst stage (day 5 and\or day 6) utilizing trophectoderm biopsy (Figure 2) 
(Harper, 2001). All of these method aims to obtain genetic samples from oocyte and embryo by 
breaching the surrounding membrane (Table 1) (Harper, 2001). And after obtaining the samples we use 
two methods which is polymerase chain reaction (PCR) and Fluorescence in situ hybridization (FISH) 
to search for genetic disorders (Figure 3) (Asscher & Koops, 2010). There some changes happened to 
the PGD technique like using calcium magnesium free as a media found to be better in reducing lysis 
of blastomere (Harper, 2012). There is also some disadvantages when we using PGD test. There have 
been a number of misdiagnoses for some cases and beside the diagnoses issues the PGD technique is an 
expensive method witch required a lot of money especially in countries like UK where the prenatal 
diagnoses paid for by the state but not PGD (Basille, 2009). And we must not forget the paint part, that 
will defiantly suffer from going through IVF and that will cost them a lot of money and make them 
stressful (Asscher & Koops, 2010).  
 
 
Figure 1. PGD Process 
 
 
Figure 2. Removal of Blastomere from 8 Cell Embryo (Blastocyst) 
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Table 1. PGD Methods for Obtaining Genetic Samples from Oocyte and Embryo by Breaching 
the Surrounding Membrane  
 Polar bodies  Cleavage stage  Blastocyst stage  
Advantages  The sample obtained early 
Which allow IFV laboratory 
maximum flexibility in terms 
of embryo transfer. 
This method allow testing 
both maternal and paternal 
genetic contribution to the 
embryo. 
The biopsy appears to 
have little if any impact 
on subsequent embryo 
development and the high 
number of cells obtained 
result in an improved 
accuracy of genetic test.  
Disadvantages  The information obtained is 
related to mother only, No 
abnormalities of paternal origin 
can be detected. 
The fragile of cleavage 
stage embryo, which 
require highly skilled 
embryologists. 
Many patients do not 
produce sufficient 
numbers of high quality 
embryos to be considered 
for culture.  
 
 
Figure 3. Abnormalities of Chromosome 13, 18, 21 
 
2. Material and Method 
2.1 Bioinformatics 
Bioinformatics is the application of computer technology to the management of biological information. 
Computers are used to gather, store, analyze and integrate biological and genetic information which can 
then be applied to gene-based drug discovery and development. The need for Bioinformatics 
capabilities has been precipitated by the explosion of publicly available genomic information resulting 
from the Human Genome Project. 
 
 
      Trisomy 13                    Trisomy 18             Trisomy 21 
www.scholink.org/ojs/index.php/rhs                   Research in Health Science                         Vol. 2, No. 4, 2017 
354 
Published by SCHOLINK INC. 
2.2 Statistical Analysis 
We used descriptive statistics, which is the discipline of quantitatively describing the main features of a 
collection of information (Asscher & Koops, 2010), or the quantitative description itself. It is 
distinguished from inferential statistics (or inductive statistics), in that descriptive statistics aim to 
summarize a sample, rather than use the data to learn about the population that the sample of data is 
thought to represent. This generally means that descriptive statistics, unlike inferential statistics, are not 
developed on the basis of probability theory (Basille, 2009; Bellavia, 2010). Even when a data analysis 
draws its main conclusions using inferential statistics, descriptive statistics are generally also presented. 
It also provides simple summaries about the sample and about the observations that have been made. 
Such summaries may be either quantitative, summary statistics, or visual (Handyside, 1990). 
 
3. Results 
3.1 Literature Review 
In the literature, we found out that the indications for Preimplantation Genetic Screening, are mostly in 
early pregnancy losses and this can be attributed to aneuploidy. Primary candidates for PGS can include 
women of advanced maternal age, couples with history of recurrent pregnancy loss, couples with 
repeated IVF failure, and male partner with severe male factor infertility.  
These patient populations are at risk of failure with IVF because of a high proportion of aneuploid 
embryos. PGD is believed to decrease this risk by selecting chromosomally normal embryos that have a 
higher chance of implantation. 
3.1.1 Advanced Maternal Age 
The risk of aneuploidy in children increases as women age. The chromosomes in the egg are less likely 
to divide properly, leading to an extra or missing chromosome in the embryo (Table 2). One of the most 
frequent aneuploidies, is trisomy of chromosome 21, which leads to Down syndrome (Table 3). 
 
Table 2. Chromosomal Abnormalities 
Age, y Embryos (Normal), % Embryos (Aneuploidy), % Other Abnormality, % 
25-35 61 8 31 
36-37 60 10 30 
38-39 47 18 35 
40-41 43 26 31 
42-44 39 30 31 
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Table 3. Frequency of Down Syndrome Per Maternal Age 
Age, y 
Frequency of Fetuses With Down Syndrome/ 
Normal Fetuses at 16 Weeks of Pregnancy 
Frequency of Live Births of Babies/ 
With Down Syndrome to Normal Births 
15-19 . . . 1/1250 
20-24 . . . 1/1400 
25-29 . . . 1/1100 
30-31 . . . 1/900 
32 . . . 1/750 
33 1/420 1/625 
34 1/325 1/500 
35 1/250 1/350 
36 1/200 1/275 
37 1/150 1/225 
38 1/120 1/175 
39 1/100 1/140 
40 1/75 1/100 
41 1/60 1/85 
42 1/45 1/65 
42 1/35 1/50 
44 1/30 1/40 
45 and older 1/20 1/25 
 
3.2 PGD in King Faisal Specialist Hospital and Research Centre  
In 2012 and 2013 the King Faisal Specialist Hospital and Research Centre published new statistics for 
PGD in local newspapers, and based on these numbers we are going to build our facts and the 
importance of PGD (Graph1). The program of PGD in 2012 King Faisal Specialist Hospital and 
Research Centre has help 300 families to put an end for their suffering. Also the program op PGD result 
in 140 cases end with succeed pregnancy, and the ratio of success is 45% to be more than the global 
success ration which is 37%. In addition the numbers of discovered diseases have change from 185 
diseases in 2012 to 224 diseases in 2013 and the number therapeutic session have reach 300 sessions in 
3013 and they aim to make it to 500 sessions every year. They reported that they help to prevent Cases 
of genetic diseases and the most important genetic diseases are thalassemia, sickle cell anemia, Cystic 
fibrosis and inherited metabolic disorders. 
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Figure 4. PGD Statistics in Saudi Arabia 
 
3.2.1 Down Syndrome 
Is a genetic disorder caused when mistake in cell division results in extra genetic material from 
chromosome 21 & have 47 chromosomes, Trisomy 21 (About 95% of all patients), Mosaic Down 
Syndrome (About 2% of Down syndrome patients) and Partial Trisomy 21 (Very rarely) Any one of three 
genetic variations can cause Down syndrome (Handarson, 2008). 
3.2.2 Sickle Cell Disease 
Sickle cell disease is an autosomal recessive disorder of hemoglobin in which the 𝛽 subunit genes 
have a missense mutation that substitutes valine for glutamic acid at amino acid 6. The disease is most 
commonly due to homozygosity for the sickle cell mutation. As a result of these disorder the Glu6Val 
mutation in 𝛽 globin decreases the solubility of deoxygenated hemoglobin and causes it to form a 
gelatinous network of stiff fibrous polymers that distort the red blood cell, giving it a sickle shape 
(Handarson, 2008).  
3.2.3 Thalassemia 
Thalassemia are autosomal recessive anemias caused by deficient synthesis of either 𝛼-globin or 
𝛽-globin. A relative deficiency of 𝛼-globin causes 𝛼-thalassemia, and a relative deficincy of 𝛽-globin 
causes 𝛽-thalassemia. The pathogenesis of thalassemia arises from inadequate hemoglobin production 
and unbalance accumulation of globin subunits, which causes hypochromic and microcytosis 
(Handarson, 2008).  
According to many studies in eastern region, the percentage of people suffering from sickle cell anemia is 
28% and 30% for thalassemia in AL-Qatif. In addition, the number of people affected with sickle cell 
anemia in Eastern and southern Provinces is significant and more common than the rest (Alsultan, 2016). 
And the newspaper claimed that there is more than 25 thousand person suffer from G6PD anemia and 
more than 24 thousand suffer from sickle cell anemia, which cost the government more than 75 million 
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R.S every year (Alsultan, 2016). And the percentage of people suffering from sickle cell anima in 
AL-Ahsa raised to 30% (Alsultan, 2016). 
3.3 Research Studies in Related PGD in Saudi Arabia and GCC 
 
 
Figure 5. Numbers of Research about PGD in Saudi Arabia and GCC 
 
Table 4. Number of Research in PGD Related to Disease 
 Saudi Arabia GCC 
PGD studies 58 43 
PGD and Diseases 49 30 
PGD and Diseases and inheritance 19 9 
Preimplantation Genetic Profiling 10 29 
Preimplantation Genetic Profiling and successful pregnancy 4 5 
 
3.4 Using PGD for X-Linked Diseases 
Hemophilia is X-linked disorders of coagulation caused by mutations in the F8 and F9 genes, 
respectively. Mutations of F8 cause deficiency or dysfunction of clotting factor VIII; mutations of F9 
cause deficiency or dysfunction of clotting factor IX (Mastenbroek, 2011). Usually affects males, so we 
can do PGD for couples at risk of having a child with hemophilia A by gender selection (Figure 6) 
(Munne, 2009). Also Hemophilia A has an incidence of 1 in 5000 to 10,000 newborn males. 
Hemophilia B is far rarer, with an incidence of 1 in 100,000. 
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Figure 6. Genetic Inheritance of Hemophilia 
 
There are two types of hemophilia: Hemophilia A: caused by defiance or absence in factor 8 (called 
Factor VIII also) in blood coagulation, and it is the most common form with 80% in all Hemophilia 
types. Hemophilia type B: caused by defiance or absence in factor 9 (also called Factor XI and 
Christmas Disease) in blood coagulation, and it’s less common than type A (Table 5). 
 
Table 5. Classification If Henophilia Based on the Severity 
 
This Causes lifelong intellectual disability and developmental delays, and in some people it causes health 
problems. 
Incidence of this dease in Riyadh to be 1 in 554 live births. The study scanned 23,261 consecutive live 
births to Saudi women over a period of nine years (1982-1991) to find 23 females and 19 males suffering 
from it. In the vast majority of these patients, the cause was non-disjunction trisomy 21. 
 
4. Discussion  
In order to be certain about our graduation project we did some searching for local and foreign statistics 
about PGD and how it help our society particularly, and we rely come out with some exciting result and 
ideas for PGD depending in many things. So to spurt our thoughts about PGD we added some statists 
CLINICAL CLASSIFICATION AND CLOTTING FACTOR LEVELS 
Classification % Activity (Factor VIII or IX) 
Severe 1% 
Moderate 1%-5% 
Mild 5%-25% 
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to clarify our point of view for PGD as a therapeutic technique and not only that but also use it for 
organ Transplantation.  
After we write above about PGD, in general we talk about result for some fields that utilize PGD 
technique like recurrent pregnancy loss and Down Syndrome Per Maternal Age (Pennings, 2003). And 
from the numbers we get we saw some good indicators for using PGD. In Advanced maternal age: 
Chromosomal Abnormalities (Table 2) we found that the percentage of having childe suffer from 
chromosomal abnormalities is increased with the age, so we can use PGD to decrease the percentage of 
having children with chromosomal abnormalities especially with 40 years and older women. Like 
Italian PGD study shows that the risk of miscarriage in women over 36 years old having PGD was 4% 
whereas the risk of the same aged women having IVF without PGD was 20% (Figure 7) (Ly, 2011). 
 
 
Figure 7. PGD in Italian Study Indicating Percentage of Successful IVF after Implantation 
 
In addition, using PGD in Saudi Arabia has proved it benefit with remarkable accomplishments, which 
as we demonstrate it in Table 3 above. The PGD in King Faisal Specialist Hospital and Research Centre 
have helped many families in our region, and some of these accomplishments is the ratio of pregnancy, 
which is 45%, and this percentage is more than the global ratio of pregnancy. Also the PGD program in 
King Faisal Specialist Hospital and Research Centre have given an end for more than 850 families 
suffer from inherited diseases. 
Another aspect of PGD is using it to avoid X-Linked diseases by gender selection. And we have 
currently in Saudi Arabia some regions suffering from inherited Hemophilia cases especially in the 
south and east regions (Noble, 2008). And the reason we chose to talk about it is because many studies 
been in 2013, claiming that there is 2000 affected person in Saudi Arabia and it is costing the Saudi 
Ministry of Health 5 million R.S each year (Penning, 2003; Alsultan, 2016). And if we put using PGD 
in our minds in some of these cases as an option for treatment by gender selection or choosing best 
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embryo it may give an end for this disease prevalence.  
The other thing we want to talk about is how the PGD can be better economically and save a lot of 
money compering to some medicine or services for people suffer from inherited disease. The patients 
how suffer from down-syndrome cost the government Education Services around 65 million R.S every 
year, and the numbers of people affecting by these mutation is 150 thousand, which a huge number for 
Saudi Arabia is. Moreover, the cost of doing PGD is start from $4000 to $8000 in the US (Table 6) 
(Sermon, 2009), we could use it on people who have history with this mutation to save many money 
and produce healthy children without any mutation (Whittaker, 2011). 
 
Table 6. IVF/PGD Cost in USA 
 Average PGS IVF costs in USA 
IVF-ICSI Cost $12,000 
IVF medication costs About $3500 
Embryo biopsy cost $1800 
PGS test cost $3500 
FET cycle cost $4000 
 
We want to talk about the challenges and obstacles we had we start writing and searching about some 
statics or even new information we could use it in our project. The misery we had whenever search and 
did not find anything useful, the suffering we go through to find any static or even an official study we 
could rely on about genetic diseases is almost ZERO. We had to go through some very old news to find 
thing we could use like the Down syndrome article it is from 2003. 
One last problem is about the annual statics book from ministry of health in Saudi Arabia, which shows 
almost nothing about genetics disease not even deaths nor effected newborn. And we guess the ministry 
of health should start to bot more affords in this point for at least better future for our children how will 
suffer from some disease they don’t have any part in.  
For the future of using PGD, we saw in increase of new field start to utilize PGD, like organ and bone 
marrow transplantation by chose the most embryos compatible with the recipient. In addition, we could 
use it for healthy families to gender selection because some families have only male or female children 
and this in our society cause many problems even sometimes caused divorce. Because some people 
think, the gender is depend on women and refuses to think that he is the reason for the childe gender. 
Moreover, for public awareness we chose to talk about PGD in Separated paper with Arabic and 
English languages if we have enough time. Because we believe, it may be easier for the people to 
understand PGD, if write about it in brief and use easier language and terms. 
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